A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).

StatusNot Yet Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Eli Lilly
365 trials monitored
See 16 trials at risk
ALS
402 trials monitored
See 22 trials at risk
The main purpose of this study in participants with Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS) is to test the safety of different doses and to determine the amount of LY3873862 that gets into the bloodstream and how long it takes the body to get rid of it. For each participant, the study will last up to approximately 13 weeks and will include 6 clinic visits.
Trial Details
NCT Number NCT07883590
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme System
Related terms Amyotrophic Lateral Sclerosis
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov